Cefamandole

Chemical compound
  • AU: B1
Routes of
administrationIntramuscular, intravenousATC code
  • J01DC03 (WHO)
Legal statusLegal status
  • UK: POM (Prescription only)
  • US: Discontinued
Pharmacokinetic dataProtein binding75%Elimination half-life48 minutesExcretionMostly renal, as unchanged drugIdentifiers
  • (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-
    3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-
    5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS Number
  • 34444-01-4 checkY 42540-40-9
PubChem CID
  • 456255
DrugBank
  • DB01326 checkY
ChemSpider
  • 401748 checkY
UNII
  • 5CKP8C2LLI
KEGG
  • D02344 checkY
ChEBI
  • CHEBI:3480 checkY
ChEMBL
  • ChEMBL1146 checkY
CompTox Dashboard (EPA)
  • DTXSID7022750 Edit this at Wikidata
ECHA InfoCard100.047.285 Edit this at WikidataChemical and physical dataFormulaC18H18N6O5S2Molar mass462.50 g·mol−13D model (JSmol)
  • Interactive image
  • O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)[C@H](O)c3ccccc3)CSc4nnnn4C)C(=O)O
  • InChI=1S/C18H18N6O5S2/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29)/t11-,13-,16-/m1/s1 checkY
  • Key:OLVCFLKTBJRLHI-AXAPSJFSSA-N checkY
  (verify)

Cefamandole (INN, also known as cephamandole) is a second-generation broad-spectrum cephalosporin antibiotic. The clinically used form of cefamandole is the formate ester cefamandole nafate, a prodrug which is administered parenterally. Cefamandole is no longer available in the United States.

The chemical structure of cefamandole, like that of several other cephalosporins, contains an N-methylthiotetrazole (NMTT or 1-MTT) side chain. As the antibiotic is broken down in the body, it releases free NMTT, which can cause hypoprothrombinemia (likely due to inhibition of the enzyme vitamin K epoxide reductase)(vitamin K supplement is recommended during therapy) and a reaction with ethanol similar to that produced by disulfiram (Antabuse), due to inhibition of aldehyde dehydrogenase.

Cefamandole has a broad spectrum of activity and can be used to treat bacterial infections of the skin, bones and joints, urinary tract, and lower respiratory tract. The following represents cefamandole MIC susceptibility data for a few medically significant microorganisms.

  • Escherichia coli: 0.12 - 400 μg/ml
  • Haemophilus influenzae: 0.06 - >16 μg/ml
  • Staphylococcus aureus: 0.1 - 12.5 μg/ml[1]

CO2 is generated during the normal constitution of cefamandole and ceftazidime, potentially resulting in an explosive-like reaction in syringes.[2]

See also

References

  1. ^ "Cefamandole sodium salt Susceptibility and 0.5 - 32 Minimum Inhibitory Concentration (MIC) Data" (PDF). The Antimicrobial Index. TOKU-E. 6 January 2020.
  2. ^ Stork CM (2006). "Antibiotics, antifungals, and antivirals". In Nelson LH, Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA (eds.). Goldfrank's toxicologic emergencies. New York: McGraw-Hill. p. 847. ISBN 0-07-143763-0. Retrieved 2009-07-03.
  • v
  • t
  • e
Beta-lactams
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Penicillins (Penams)
Narrow
spectrum
β-lactamase sensitive
(1st generation)
β-lactamase resistant
(2nd generation)
Extended
spectrum
Aminopenicillins (3rd generation)
Carboxypenicillins (4th generation)
Ureidopenicillins (4th generation)
Other
Carbapenems / Penems
Cephems
Cephalosporins
Cephamycins
Carbacephems
1st generation
2nd generation
3rd generation
4th generation
5th generation
Siderophore
Veterinary
Monobactams
β-lactamase inhibitors
Combinations
Polypeptides
Glycopeptides
Lipoglycopeptides
Lipopeptides
Polymyxins
Other
  • Inhibits PG elongation and crosslinking: Ramoplanin§
Intracellular
Other